Incidence and risk of vaginal candidiasis associated with sodium–glucose cotransporter 2 inhibitors in real‐world practice for women with type 2 diabetes

AIMS/INTRODUCTION: The prevalence and risk of vaginal candidiasis before and after initiating sodium–glucose cotransporter 2 (SGLT2) inhibitors, although some clinical trials have been carried out, have not been adequately shown in real‐world practice. We investigated the incidence of vaginal Candid...

Descripción completa

Detalles Bibliográficos
Autores principales: Yokoyama, Hiroki, Nagao, Ami, Watanabe, Sanae, Honjo, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400166/
https://www.ncbi.nlm.nih.gov/pubmed/30136398
http://dx.doi.org/10.1111/jdi.12912

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400166/
https://www.ncbi.nlm.nih.gov/pubmed/30136398
http://dx.doi.org/10.1111/jdi.12912

Ejemplares similares